Put These Two Promising Biotech Stocks on Your Watch List
by Louis Basenese, Small Cap and Special Situations Expert
Friday, November 6, 2009: Issue #1132
All the hoopla surrounding the biotech stock, Dendreon Corp. (Nasdaq: DNDN), this year is well deserved.
After all, the market potential for its prostate cancer treatment, Provenge, is significant. This year, 190,000 new cases of prostate cancer are expected, with 27,000 deaths from the disease. That makes it the most common non-skin cancer in the United States and the third most common cancer worldwide.
But Provenge takes a novel approach to treatment. The drug is the first active immunotherapy to improve survival by training a patient’s immune system to attack the cancer. And since it uses the body’s natural defenses, patients only report flu-like symptoms instead of the nasty side effects associated with chemotherapy.
This could have a far-reaching effect: If Dendreon’s methodology works to combat prostate cancer, it may also work in combating other cancers, too.
If so, then forget blockbuster… we’re talking mega-blockbuster here. Two Promising Biotech Stocks – Full Article
Latest From Our Experts
![]() |
Wealth Building:
What If Jeremy Grantham is Right?
|
![]() |
Small Caps: Dendreon Corp. (Nasdaq: DNDN): Put These Two Promising Biotech Stocks on Your Watch Listby Louis Basenese |
![]() |
Energy & Infrastructure: Warren Buffett Goes “All in” on America… How to Play the Oracle’s Big Betby David Fessler |
![]() |
Healthcare: The Stock Market’s Red Flags: Four Ways to Handle Potential Market Turmoilby Marc Lichtenfeld |
![]() |
Options: The Married Put Option Strategy: The Smartest Way to Protect Against Downsideby Karim Rahemtulla |
![]() |
|
Sponsored Link: Legally "Eavesdrop" on this Private Gathering of Top Technology CEOs
Dendreon’s Reached Orbit… Now Who’s Next?
by Robert Williams, Publisher
When the opening bell rang on Tuesday morning, as the broader market sagged, shares of Dendreon Corp. (Nasdaq: DNDN) sprinted out of the gates, rising by 5.7%.
Unless you live in a cave, you should know about this biotech stock.
Back in April, shares went “parabolic,” blasting 454% higher during the month.
(That’s not a typo. The stock increased almost five-fold over the course of a single month, rendering the S&P 500’s 10% gain over the same period completely insignificant.)
With an impressive move like that, you might think the run is over. But shares will likely head higher still… Full Article
![]() |
|















Investment U RSS Feed